hotspot -WSS

hotspot

author：Wikipedia 2025-09-27 10:01:30 - browse：1

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Wikipedia

leisure time

WSS

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Surge of respiratory disease in China has likely explanation

Why medical students are struggling with mental health

Surge of respiratory disease in China has likely explanation

Ukraine and a new approach to mental health in war

Medical student insurance fails on mental health care coverage

entertainment

hotspot

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: A CRISPR milestone, biotech mixology

In Memoriam: Notable people who died in 2023

Morphosys mixed study results for blood cancer drug

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Intarcia’s device

As demand for Covid shots wanes, Moderna seeks its next success

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Novavax promises a turnaround & Lilly roils the obesity market

CommonSpirit Health keeps growing, even as it loses money

focus

Hospitals look to new technology to keep health care workers safe

David Sabatini, ex

Anthos stroke drug appears safer than common blood thinner

Lasker Awards 2023: Winners in biomedical research

Astellas still sees hope in its gene therapy after four deaths

A daunting task: navigating dual Medicare, Medicaid eligibility

Wikipedia

leisure time

hotspot

entertainment